Objective:

To investigate how antibiotic-induced gut microbiota disruption impacts glioma progression using a multi-omics approach.

Approach:

• Study Design: Utilized single-cell transcriptomics, spatial transcriptomics, metagenomics, metabolomics, and m6A-seq in a mouse model.
• Gene Expression Analysis: Performed RNA sequencing to identify differentially expressed genes in glioma-bearing mice treated with antibiotics.
• Metabolomic Profiling: Analyzed metabolite levels in gliomas to link gut-derived changes to epigenetic regulation.
• Single-Cell RNA Sequencing: Examined cellular composition and intercellular communication in gliomas.

Key Findings:

• ABX-treated mice showed reduced expression of Epha6 and increased expression of Tead1, both associated with glioma progression.
• Metabolomic profiling revealed decreased methionine levels in gliomas from ABX-treated mice.
• Single-cell RNA sequencing indicated an increased proportion of AC-like cells and disrupted intercellular communication.

Interpretation:

The study investigates the relationship between gut microbiota, immune signaling, and epigenetic modifications in glioma biology.

Limitations:

• The study was conducted in a mouse model, which may not fully replicate human glioma biology.
• The precise mechanisms linking gut microbiota changes to glioma progression require further investigation.

Conclusion:

The findings provide insights into the role of the gut-brain axis in glioma regulation.